Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Hartley-Brown's clinical area of focus is treating patients with Multiple Myeloma. This is an incurable blood cancer, that affects African Americans more prevalently than other ethnic populations. She also practices clinical research, mainly in the relapsed refractory myeloma disease setting. Dr. Hartley-Brown actively participates as a principal investigator in clinical trials within the Alliance for Clinical Trials, investigator-initiated and investigator sponsored trials. Her area of interest in clinical trials includes use of immunotherapies and targeted therapies, such as bispecific/tri-specific antibodies, antibody-drug conjugates and modern immune modulating drugs (ex. cereblon modulators).
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions